[1] A randomised phase III study of regorafenib against placebo and best supportive care in patients with refractory colorectal carcinoma (CRC) including prior therapy with bevacizumab, cetuximab or panitumumab in KRAS wild-type tumours showed improvement of progression free survival (PFS) as well as overall survival (OS) in favour of regorafenib treatment, establishing a new standard of care in this study population [2].However, OS benefit was a modest 1.4 months, contributed mainly by disease control rather than tumour shrinkage. The gene discussed is KRAS; the disease is colorectal carcinoma.